View highlights and coverage from leading international Neurology congresses
We were delighted to have an opportunity to hear all about the Stroke Action Plan for Europe from Arlene Wilkie, Director General of the Stroke Alliance for Europe (SAFE). Related useful resources: Stroke Alliance for Europe (SAFE) Economic Impact of Stroke in Europe Questions What are the major challenges in stroke care across Europe and […]
We were delighted to have the opportunity to speak with Indu Subramanian (Geffen School of Medicine, UCLA, and West Los Angeles Veterans Administration, Los Angeles, CA, USA) around the focus of her recently published article entitled: Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life, which was highlighted as a top […]
It was an honour to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) around his presentation, a sub analysis of the OPTIMUM study (ClinicalTrials.gov identifier: NCT02425644), entitled: P0071 – Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study. Questions […]
We were delighted to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) about his highlights from the MSVirtual2020 meeting. Disclosures: Dr Kappos reports receiving grants from Actelion, Allergan, Almirall, Baxalta, Bayer Healthcare, Biogen, CSL Behring, Desitin, Eisai, Excemed, Genzyme, INNO Swiss, Japan Tabacco, Merck, Novartis, Roche, Pfizer, Receptos, Sanofi, Santhera and […]
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. What is known about the role of inflammation in the […]
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. Could you tell us about the design of your phase […]
It was a pleasure to speak with Camille Carroll (University of Plymouth, Plymouth, UK) about her late-breaking presentation entitled: Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): results of a double-blind, randomised, placebo-controlled futility study. ClinicalTrials.gov Identifier: NCT02787590. Questions What was the scientific rationale for investigating simvastatin as a neuroprotective treatment for Parkinson’s disease (PD)? (0:06) […]
Get the latest clinical insights from touchNEUROLOGY
